The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis
- 1 January 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 44 (1) , 89-93
- https://doi.org/10.1067/mjd.2001.111352
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildrenJournal of Allergy and Clinical Immunology, 1999
- Leukotrienes in the Pathogenesis of AsthmaChest, 1997
- The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis.American Journal of Respiratory and Critical Care Medicine, 1995
- The Role of Leukotrienes in InflammationAnnals of Internal Medicine, 1994
- Leukotriene E4 and granulocytic infiltration into asthmatic airwaysThe Lancet, 1993
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase InhibitorNew England Journal of Medicine, 1990
- Leukotrienes and Other Products of the 5-Lipoxygenase PathwayNew England Journal of Medicine, 1990
- Effect of the oral leukotriene D antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D in atopic subjectsJournal of Allergy and Clinical Immunology, 1989
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983